Relationship Between Homocysteine and BMD

Fundación Santiago Dexeus Font

Status: Completed

Conditions: Postmenopausal Women

Treatments: Diagnostic Test: Dual-Energy X-ray Absorptiometry (DXA)

Study type: Observational

Funder types: Other

Identifiers

NCT04821492

FSD-HCY-2020-05

Details and patient eligibility

About

The association between Homocysteine (Hcy) levels and bone mineral density (BMD) has been debated. Some studies have found a relationship between increased Hcy plasma levels and BMD in contrast; other studies have not found a relationship. The purpose of our study was to investigate whether or not Hcy plasma levels are related to BMD in a group of postmenopausal women.

Enrollment: 760 patients

Sex: Female

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal women
• BMD measured by dual-energy X-ray absorptiometry (DXA)

Exclusion criteria

• Primary ovarian failure
• Early menopause
• Cardiovascular, liver, or renal diseases
• Surgical menopause
• History of cancer
• Receiving treatment known to influence levels of Hcy or bone mineralization (folates or vitamin B12 supplements, menopausal hormonal treatment, corticosteroids, anticonvulsants, heparin, thiazide diuretics, and antiresorptive agents).

Trial design

760 participants in 2 patient groups

Hyperhomocysteinemia

Treatment:

Diagnostic Test: Dual-Energy X-ray Absorptiometry (DXA)

Normal Hcy levels

Treatment:

Diagnostic Test: Dual-Energy X-ray Absorptiometry (DXA)